bioAffinity
  • Home
  • Publications
  • News
  • About
  • Contact
  • Investor Relations
Select Page
  • Home
  • Publications
  • News
  • About
  • Contact
  • Investor Relations

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Jan 24, 2023 8:00am EST

bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research

Jan 04, 2023 8:00am EST

bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments

Dec 15, 2022 8:30am EST

bioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical Bench

Dec 01, 2022 8:00am EST

bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting

Nov 14, 2022 7:30am EST

bioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 10, 2022 8:15am EST

bioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Company’s Scientific and Medical Advisory Board

Nov 08, 2022 8:00am EST

bioAffinity Technologies to Report Third Quarter 2022 Financial Results

Oct 25, 2022 9:15am EDT

bioAffinity Technologies Announces Award of Therapeutic Patents in China, Mexico and Australia

Oct 12, 2022 8:15am EDT

bioAffinity Technologies Presents Results from Flow Cytometry Analysis of the Lung at CHEST Conference

Sep 28, 2022 8:15am EDT

bioAffinity Technologies Receives Additional $7.7M from Exercise of Warrants, Total Capital from Public Offering Increases to Approximately $15.6M

  • arrow_back
  • 1…
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • …14
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed


Phone

(210) 698-5334



Email

info@bioaffinitytech.com



LinkedIn

…/bioaffinitytechnologies



Twitter

@bioAffinity

Subscribe for News from bioAffinity Technologies

Subscribe
Copyright © 2025 bioAffinity Technologies, Inc.